Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 841

1.

Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.

Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, Lynch HT, Singer CF, Senter L, Neuhausen SL, Tung N, Eisen A, Foulkes WD, Ainsworth P, Sun P, Lubinski J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

Gynecol Oncol. 2018 Jul;150(1):85-91. doi: 10.1016/j.ygyno.2018.05.011. Epub 2018 May 21.

PMID:
29793803
2.

Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Gronwald J, Lynch HT, Eisen A, Neuhausen SL, Tung N, Ainsworth P, Weitzel JN, Pal T, Foulkes WD, Eng C, Singer CF, Senter L, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2018 May 17. doi: 10.1007/s10549-018-4822-y. [Epub ahead of print]

PMID:
29774471
3.

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.

Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

JAMA Oncol. 2018 Apr 19. doi: 10.1001/jamaoncol.2018.0211. [Epub ahead of print]

PMID:
29710224
4.

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.

Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip J, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, Lipkin SM.

Cancer Res. 2018 May 15;78(10):2747-2759. doi: 10.1158/0008-5472.CAN-17-1900. Epub 2018 Mar 20.

PMID:
29559475
5.

Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers.

Kim SJ, Huzarski T, Gronwald J, Singer CF, Møller P, Lynch HT, Armel S, Karlan BY, Foulkes WD, Neuhausen SL, Senter L, Eisen A, Eng C, Panchal S, Pal T, Olopade O, Zakalik D, Lubinski J, Narod SA, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group.

Int J Epidemiol. 2018 Mar 13. doi: 10.1093/ije/dyy039. [Epub ahead of print]

PMID:
29547931
6.

Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Lammert J, Lubinski J, Gronwald J, Huzarski T, Armel S, Eisen A, Meschino WS, Lynch HT, Snyder C, Eng C, Olopade OI, Ginsburg O, Foulkes WD, Elser C, Cohen SA, Kiechle M, Narod SA, Kotsopoulos J.

Breast Cancer Res Treat. 2018 Jun;169(3):561-571. doi: 10.1007/s10549-018-4694-1. Epub 2018 Feb 5.

PMID:
29404807
7.

The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.

Ko KP, Kim SJ, Huzarski T, Gronwald J, Lubinski J, Lynch HT, Armel S, Park SK, Karlan B, Singer CF, Neuhausen SL, Narod SA, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group.

Int J Cancer. 2018 Jun 1;142(11):2263-2272. doi: 10.1002/ijc.31257. Epub 2018 Jan 25.

PMID:
29330845
8.

The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer.

Metcalfe KA, Lubinski J, Gronwald J, Huzarski T, McCuaig J, Lynch HT, Karlan B, Foulkes WD, Singer CF, Neuhausen SL, Senter L, Eisen A, Sun P, Narod SA; and the Hereditary Breast Cancer Clinical Study Group.

Clin Genet. 2018 May;93(5):1063-1068. doi: 10.1111/cge.13191. Epub 2018 Mar 25.

PMID:
29206279
9.

Efficacy of proximal colectomy for surgical management of right-sided first colorectal cancer in Lynch Syndrome mutation carriers.

Hiatt MJ, Casey MJ, Lynch HT, Snyder CL, Stacey M, Walters RW.

Am J Surg. 2018 Jul;216(1):99-105. doi: 10.1016/j.amjsurg.2017.11.003. Epub 2017 Nov 8.

PMID:
29153248
10.

Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge.

Lynch HT, Lanspa S, Shaw T, Casey MJ, Rendell M, Stacey M, Townley T, Snyder C, Hitchins M, Bailey-Wilson J.

Fam Cancer. 2018 Jul;17(3):403-414. doi: 10.1007/s10689-017-0053-3. Review.

PMID:
29071502
11.

Curcumin: An age-old anti-inflammatory and anti-neoplastic agent.

Fadus MC, Lau C, Bikhchandani J, Lynch HT.

J Tradit Complement Med. 2016 Sep 9;7(3):339-346. doi: 10.1016/j.jtcme.2016.08.002. eCollection 2017 Jul. Review.

12.

Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.

Liede A, Mansfield CA, Metcalfe KA, Price MA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG.

Breast Cancer Res Treat. 2017 Sep;165(2):433-444. doi: 10.1007/s10549-017-4332-3. Epub 2017 Jun 17.

13.

Major hereditary gastrointestinal cancer syndromes: a narrative review.

Chintalacheruvu LM, Shaw T, Buddam A, Diab O, Kassim T, Mukherjee S, Lynch HT.

J Gastrointestin Liver Dis. 2017 Jun;26(2):157-163. doi: 10.15403/jgld.2014.1121.262.maj. Review.

14.

Mutations in the Histone Modifier PRDM6 Are Associated with Isolated Nonsyndromic Patent Ductus Arteriosus.

Li N, Subrahmanyan L, Smith E, Yu X, Zaidi S, Choi M, Mane S, Nelson-Williams C, Behjati M, Kazemi M, Hashemi M, Fathzadeh M, Narayanan A, Tian L, Montazeri F, Mani M, Begleiter ML, Coon BG, Lynch HT, Olson EN, Zhao H, Ruland J, Lifton RP, Mani A.

Am J Hum Genet. 2016 Oct 6;99(4):1000. doi: 10.1016/j.ajhg.2016.09.003. No abstract available.

15.

Commentary on Almassalha et al., "The Greater Genomic Landscape: The Heterogeneous Evolution of Cancer".

Lynch HT, Rendell M, Shaw TG, Silberstein P, Ngo BT.

Cancer Res. 2016 Oct 1;76(19):5602-5604. Epub 2016 Sep 16.

16.

Therapeutic and Preventive Implications of Moonshot in Hereditary Cancer Syndromes.

Diab O, Chintalacheruvu LM, Lynch HT.

JAMA Oncol. 2017 May 1;3(5):592-593. doi: 10.1001/jamaoncol.2016.3046. No abstract available.

PMID:
27607995
17.

Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.

Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, Armel S, Karlan B, Foulkes WD, Neuhausen SL, Senter L, Tung N, Weitzel JN, Eisen A, Metcalfe K, Eng C, Pal T, Evans G, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

J Natl Cancer Inst. 2016 Sep 6;109(1). pii: djw177. doi: 10.1093/jnci/djw177. Print 2017 Jan.

PMID:
27601060
18.

Introduction to special issue of Familial Cancer.

Lynch HT, Snyder CL.

Fam Cancer. 2016 Jul;15(3):357-8. doi: 10.1007/s10689-016-9909-1. No abstract available.

PMID:
27240898
19.

Mutations in the Histone Modifier PRDM6 Are Associated with Isolated Nonsyndromic Patent Ductus Arteriosus.

Li N, Subrahmanyan L, Smith E, Yu X, Zaidi S, Choi M, Mane S, Nelson-Williams C, Behjati M, Kazemi M, Hashemi M, Fathzadeh M, Narayanan A, Tian L, Montazeri F, Mani M, Begleiter ML, Coon BG, Lynch HT, Olson EN, Zhao H, Ruland J, Lifton RP, Mani A.

Am J Hum Genet. 2016 Jun 2;98(6):1082-1091. doi: 10.1016/j.ajhg.2016.03.022. Epub 2016 May 12. Erratum in: Am J Hum Genet. 2016 Oct 6;99(4):1000.

20.

Family Chronicles of Missed Opportunities.

Flugelman AA, Lynch HT.

JAMA Oncol. 2016 Apr 14. doi: 10.1001/jamaoncol.2016.0110. [Epub ahead of print] No abstract available.

PMID:
27078253
21.

Lynch syndrome in South America: past, present and future.

Vaccaro CA, Sarroca C, Rossi B, Lopez-Kostner F, Dominguez M, Calo NC, Cutait R, Valle AD, Nuñez L, Neffa F, Alvarez K, Gonzalez ML, Kalfayan P, Lynch HT, Church J.

Fam Cancer. 2016 Jul;15(3):437-45. doi: 10.1007/s10689-016-9903-7.

PMID:
27007491
22.

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study.

Iqbal J, Nussenzweig A, Lubinski J, Byrski T, Eisen A, Bordeleau L, Tung NM, Manoukian S, Phelan CM, Sun P, Narod SA; Hereditary Breast Cancer Research Group.

Br J Cancer. 2016 May 10;114(10):1160-4. doi: 10.1038/bjc.2016.58. Epub 2016 Mar 17.

23.

Familial atypical multiple mole melanoma (FAMMM) syndrome: history, genetics, and heterogeneity.

Lynch HT, Shaw TG.

Fam Cancer. 2016 Jul;15(3):487-91. doi: 10.1007/s10689-016-9888-2.

PMID:
26892865
24.

Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.

Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, Senter L, Demsky R, Foulkes WD, Eng C, Karlan B, Tung N, Singer CF, Sun P, Lubinski J, Narod SA.

Breast Cancer Res Treat. 2016 Jan;155(2):365-73. doi: 10.1007/s10549-016-3685-3. Epub 2016 Jan 16.

PMID:
26780555
25.

Familial Carcinoma of Unknown Primary.

Lynch HT, Slostad B, Silberstein P.

JAMA Oncol. 2016 Mar;2(3):346-7. doi: 10.1001/jamaoncol.2015.4653. No abstract available.

PMID:
26720158
26.

Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.

Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, Moller P, Ainsworth P, Sun P, Narod SA, Lubinski J, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group.

Fertil Steril. 2016 Mar;105(3):781-785. doi: 10.1016/j.fertnstert.2015.11.034. Epub 2015 Dec 14.

PMID:
26698676
27.

Screening for familial and hereditary prostate cancer.

Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D'Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.

Int J Cancer. 2016 Jun 1;138(11):2579-91. doi: 10.1002/ijc.29949. Epub 2016 Feb 5. Review.

28.

Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?

Semple J, Metcalfe KA, Lubinski J, Huzarski T, Gronwald J, Armel S, Lynch HT, Karlan B, Foulkes W, Singer CF, Neuhausen SL, Eng C, Iqbal J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2015 Nov;154(1):163-9.

PMID:
26467043
29.

Weight gain after oophorectomy among women with a BRCA1 or BRCA2 mutation.

Kotsopoulos J, Lubinski J, Neuhausen SL, Gronwald J, Lynch HT, Huzarski T, Demsky R, Foulkes WD, Senter L, Friedman S, Ainsworth P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Womens Health (Lond). 2015 Jul;11(4):453-9. doi: 10.2217/WHE.15.4. Epub 2015 Aug 10.

PMID:
26258912
30.

Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome.

Guindalini RS, Win AK, Gulden C, Lindor NM, Newcomb PA, Haile RW, Raymond V, Stoffel E, Hall M, Llor X, Ukaegbu CI, Solomon I, Weitzel J, Kalady M, Blanco A, Terdiman J, Shuttlesworth GA, Lynch PM, Hampel H, Lynch HT, Jenkins MA, Olopade OI, Kupfer SS.

Gastroenterology. 2015 Nov;149(6):1446-53. doi: 10.1053/j.gastro.2015.07.052. Epub 2015 Aug 3.

31.

Should risk-reducing surgery in women from hereditary breast ovarian cancer families be confined to removal of the fallopian tubes with ovarian conservation?

Snyder CL, Casey MJ, Lynch HT.

Womens Health (Lond). 2015 Jul;11(4):423-7. doi: 10.2217/whe.15.26. Epub 2015 Aug 6. No abstract available.

PMID:
26246179
32.

Lynch syndrome in the 21st century: clinical perspectives.

Tiwari AK, Roy HK, Lynch HT.

QJM. 2016 Mar;109(3):151-8. doi: 10.1093/qjmed/hcv137. Epub 2015 Jul 29. Review.

PMID:
26224055
33.

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, Eisen A, Rosen B, Snyder C, Gershman S, Sun P, Narod SA.

JAMA Oncol. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658.

PMID:
26181175
34.

Novel MSH2 Mutation in the First Report of a Vietnamese-American Kindred with Lynch Syndrome.

Eskander RN, Lynch HT, Brown SM, Wagman LD, Tewari KS.

Gynecol Oncol Rep. 2015 Feb 26;12:31-3. doi: 10.1016/j.gore.2015.02.003. eCollection 2015 Apr.

35.

Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Cybulski C, Lubinski J, Huzarski T, Lynch HT, Randall SA, Neuhausen SL, Senter L, Friedman S, Ainsworth P, Singer C, Foulkes WD, Narod SA, Sun P, Kotsopoulos J.

Breast Cancer Res Treat. 2015 Jun;151(2):435-41. doi: 10.1007/s10549-015-3393-4. Epub 2015 May 3.

PMID:
25935583
36.

Microsatellite instability, disease-free survival and role of tumour infiltrating lymphocytes (Invited editorial on 'Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicenter study').

Lynch HT, Lanspa SJ, Snyder CL, Drescher KM.

Eur J Cancer. 2015 May;51(8):922-4. doi: 10.1016/j.ejca.2015.03.012. Epub 2015 Apr 13. No abstract available.

PMID:
25883012
37.

PMS2 monoallelic mutation carriers: the known unknown.

Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, Clendenning M, Win AK, Senter L, Lipkin SM, Stadler ZK, Macrae FA, Lynch HT, Weitzel JN, de la Chapelle A, Syngal S, Lynch P, Parry S, Jenkins MA, Gallinger S, Holter S, Aronson M, Newcomb PA, Burnett T, Le Marchand L, Pichurin P, Hampel H, Terdiman JP, Lu KH, Thibodeau S, Lindor NM.

Genet Med. 2016 Jan;18(1):13-9. doi: 10.1038/gim.2015.27. Epub 2015 Apr 9. Review.

38.

Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.

Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA; Hereditary Breast Cancer Study Group.

Fam Cancer. 2015 Sep;14(3):383-91. doi: 10.1007/s10689-015-9798-8.

39.

Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.

Downs B, Kim YC, Xiao F, Snyder C, Chen P, Fleissner EA, Becirovic D, Wen H, Sherman S, Cowan KH, Lynch HT, Wang SM.

Breast Cancer Res Treat. 2015 May;151(1):219-24. doi: 10.1007/s10549-015-3358-7. Epub 2015 Apr 2.

PMID:
25833210
40.

Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.

Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, Petit A, Català I, Brunet J, Feliubadaló L, Tornero E, Benítez J, Osorio A, Ramón y Cajal T, Nevanlinna H, Aittomäki K, Arun BK, Toland AE, Karlan BY, Walsh C, Lester J, Greene MH, Mai PL, Nussbaum RL, Andrulis IL, Domchek SM, Nathanson KL, Rebbeck TR, Barkardottir RB, Jakubowska A, Lubinski J, Durda K, Jaworska-Bieniek K, Claes K, Van Maerken T, Díez O, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, de la Hoya M, Caldés T, Dunning AM, Oliver C, Fineberg E, Cook M, Peock S, McCann E, Murray A, Jacobs C, Pichert G, Lalloo F, Chu C, Dorkins H, Paterson J, Ong KR, Teixeira MR; Teixeira, Hogervorst FB, van der Hout AH, Seynaeve C, van der Luijt RB, Ligtenberg MJ, Devilee P, Wijnen JT, Rookus MA, Meijers-Heijboer HE, Blok MJ, van den Ouweland AM, Aalfs CM, Rodriguez GC, Phillips KA, Piedmonte M, Nerenstone SR, Bae-Jump VL, O'Malley DM, Ratner ES, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Bojesen A, Pedersen IS, Sunde L, Jensen UB, Thomassen M, Kruse TA, Foretova L, Peterlongo P, Bernard L, Peissel B, Scuvera G, Manoukian S, Radice P, Ottini L, Montagna M, Agata S, Maugard C, Simard J, Soucy P, Berger A, Fink-Retter A, Singer CF, Rappaport C, Geschwantler-Kaulich D, Tea MK, Pfeiler G; BCFR, John EM, Miron A, Neuhausen SL, Terry MB, Chung WK, Daly MB, Goldgar DE, Janavicius R, Dorfling CM, van Rensburg EJ, Fostira F, Konstantopoulou I, Garber J, Godwin AK, Olah E, Narod SA, Rennert G, Paluch SS, Laitman Y, Friedman E; SWE-BRCA, Liljegren A, Rantala J, Stenmark-Askmalm M, Loman N, Imyanitov EN, Hamann U; kConFab Investigators, Spurdle AB, Healey S, Weitzel JN, Herzog J, Margileth D, Gorrini C, Esteller M, Gómez A, Sayols S, Vidal E, Heyn H; GEMO, Stoppa-Lyonnet D, Léoné M, Barjhoux L, Fassy-Colcombet M, de Pauw A, Lasset C, Ferrer SF, Castera L, Berthet P, Cornelis F, Bignon YJ, Damiola F, Mazoyer S, Sinilnikova OM, Maxwell CA, Vijai J, Robson M, Kauff N, Corines MJ, Villano D, Cunningham J, Lee A, Lindor N, Lázaro C, Easton DF, Offit K, Chenevix-Trench G, Couch FJ, Antoniou AC, Pujana MA.

PLoS One. 2015 Apr 1;10(4):e0120020. doi: 10.1371/journal.pone.0120020. eCollection 2015.

41.

Prevalence of PALB2 mutations in the Creighton University Breast Cancer Family Registry.

Snyder C, Metcalfe K, Sopik V, Royer R, Zhang S, Narod SA, Akbari MR, Lynch HT.

Breast Cancer Res Treat. 2015 Apr;150(3):637-41. doi: 10.1007/s10549-015-3347-x. Epub 2015 Mar 21.

PMID:
25794774
42.

Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds: report from the Creighton University Hereditary Cancer Registry with review of the implications.

Casey MJ, Bewtra C, Lynch HT, Snyder CL, Stacey M.

Int J Gynecol Cancer. 2015 May;25(4):650-6. doi: 10.1097/IGC.0000000000000402.

PMID:
25756400
43.

Milestones of Lynch syndrome: 1895-2015.

Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP.

Nat Rev Cancer. 2015 Mar;15(3):181-94. doi: 10.1038/nrc3878. Epub 2015 Feb 12. Review.

PMID:
25673086
44.

Identification of six new susceptibility loci for invasive epithelial ovarian cancer.

Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S; EMBRACE, Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM; GEMO Study Collaborators, Damiola F, Mazoyer S, Stoppa-Lyonnet D, Claes K, De Leeneer K, Kirk J, Rodriguez GC, Piedmonte M, O'Malley DM, de la Hoya M, Caldes T, Aittomäki K, Nevanlinna H, Collée JM, Rookus MA, Oosterwijk JC; Breast Cancer Family Registry, Tihomirova L, Tung N, Hamann U, Isaccs C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB; HEBON, Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira MR; KConFab Investigators, Pankratz VS, Wang X, Lindor N, Szabo CI, Kauff N, Vijai J, Aghajanian CA, Pfeiler G, Berger A, Singer CF, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Tchatchou S, Andrulis IL, Glendon G, Toland AE, Jensen UB, Kruse TA, Thomassen M, Bojesen A, Zidan J, Friedman E, Laitman Y, Soller M, Liljegren A, Arver B, Einbeigi Z, Stenmark-Askmalm M, Olopade OI, Nussbaum RL, Rebbeck TR, Nathanson KL, Domchek SM, Lu KH, Karlan BY, Walsh C, Lester J; Australian Cancer Study (Ovarian Cancer Investigators); Australian Ovarian Cancer Study Group, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, Chang-Claude J, Wang-Gohrke S, Eilber U, Moysich KB, Odunsi K, Sucheston L, Lele S, Wilkens LR, Goodman MT, Thompson PJ, Shvetsov YB, Runnebaum IB, Dürst M, Hillemanns P, Dörk T, Antonenkova N, Bogdanova N, Leminen A, Pelttari LM, Butzow R, Modugno F, Kelley JL, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Matsuo K, Hosono S, Orsulic S, Jensen A, Kjaer SK, Hogdall E, Hasmad HN, Azmi MA, Teo SH, Woo YL, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Bruinsma F, Giles GG, Liang D, Hildebrandt MA, Wu X, Levine DA, Bisogna M, Berchuck A, Iversen ES, Schildkraut JM, Concannon P, Weber RP, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, Olson SH, Krakstad C, Salvesen HB, Tangen IL, Bjorge L, van Altena AM, Aben KK, Kiemeney LA, Massuger LF, Kellar M, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Cybulski C, Yang H, Lissowska J, Brinton LA, Wentzensen N, Hogdall C, Lundvall L, Nedergaard L, Baker H, Song H, Eccles D, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Ji BT, Zheng W, Shu XO, Gao YT, Rosen B, Risch HA, McLaughlin JR, Narod SA, Monteiro AN, Chen A, Lin HY, Permuth-Wey J, Sellers TA, Tsai YY, Chen Z, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Harrington P, Lee AW, Wu AH, Pearce CL, Coetzee G, Pike MC, Dansonka-Mieszkowska A, Timorek A, Rzepecka IK, Kupryjanczyk J, Freedman M, Noushmehr H, Easton DF, Offit K, Couch FJ, Gayther S, Pharoah PP, Antoniou AC, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1 and BRCA2.

Nat Genet. 2015 Feb;47(2):164-71. doi: 10.1038/ng.3185. Epub 2015 Jan 12.

45.

Commentary on 'Colonoscopy screening compliance and outcomes in patients with Lynch syndrome'.

Bikhchandani J, Lynch HT.

Colorectal Dis. 2015 Jan;17(1):46-9. doi: 10.1111/codi.12841. No abstract available.

PMID:
25536883
46.

Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Gronwald J, Cybulski C, Demsky R, Neuhausen SL, Kim-Sing C, Tung N, Friedman S, Senter L, Weitzel J, Karlan B, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Int J Cancer. 2015 Sep 1;137(5):1136-46. doi: 10.1002/ijc.29386. Epub 2014 Dec 18.

47.

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.

Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, Vranic S, Lynch HT, Von Hoff DD, Hamid O.

Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70. doi: 10.1158/1055-9965.EPI-14-0654. Epub 2014 Nov 12.

48.

Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.

Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Tung N, Weitzel JN, Couch FJ, Hulick PJ, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Blum JL, Domchek SM, Chen J, Rebbeck TR.

Breast Cancer Res Treat. 2014 Nov;148(2):397-406. doi: 10.1007/s10549-014-3134-0. Epub 2014 Oct 14.

49.

The evolution of colorectal cancer genetics-Part 2: clinical implications and applications.

Schlussel AT, Gagliano RA Jr, Seto-Donlon S, Eggerding F, Donlon T, Berenberg J, Lynch HT.

J Gastrointest Oncol. 2014 Oct;5(5):336-44. doi: 10.3978/j.issn.2078-6891.2014.068. Review.

50.

The evolution of colorectal cancer genetics-Part 1: from discovery to practice.

Schlussel AT, Gagliano RA Jr, Seto-Donlon S, Eggerding F, Donlon T, Berenberg J, Lynch HT.

J Gastrointest Oncol. 2014 Oct;5(5):326-35. doi: 10.3978/j.issn.2078-6891.2014.069. Review.

Supplemental Content

Loading ...
Support Center